Eloxatin
Cancer, Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Cancer, Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin Merck Sharp & Dohme LLC | Phase 1 | CC |
Capecitabine Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
CIS-DIAMMINEDICHLOROPLATINUM II Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
Pembrolizumab Merck Sharp & Dohme LLC | Phase 1 | CC |
Irinotecan Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
FLUOROURACILUM Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
ETOPOSIDE Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
Cyclophosphamide Merck Sharp & Dohme LLC | Phase 1 | CC |
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →